Visit Portfolio Companies

Advaxis, Inc. (ADXS)

Advaxis is a biotechnology company that uses a harmless bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer.  A vaccine of incapacitated bacteria infiltrate cancer cells. The body attacks the cells containing or marked by the bacteria, killing the cancer cells.

Antigenics (AGEN)

Biotechnology company developing cancer vaccines and other treatments for cancer and infectious diseases.

BioVest International, Inc. (BVTI)

Biovest International develops personalized immunotherapies for life threatening cancers of the blood system.

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.

CEL-SCI (CVM)

CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system.

Dendreon (DNDN)

To target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Generex Biotechnology Corporation (GNBT)

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).

Hadron Systems, Inc. (Private) 

Widely recognized by cancer immunologists is the communicative role of tumor stromal cells that shield tumors from the immune system, and the potential of vaccines with inhibiting properties. Hadron Systems, Inc. - a privately held company - represents the targeting and ablation of tumor stroma via targeting/nucleus internalization in combination with particle therapy (the product). The product is classified as a medical device, and a clinical trial to include late-stage cancer patients is planned for September 2012.

ImmunoCellular Therapeutics, Ltd. (IMUC)

ImmunoCellular Therapeutics, Ltd. (OTC:IMUC.OB) We are a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. Our product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. Our main disease focus using our immunotherapy technologies is to treat glioblastoma, but these therapies may also be applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Our antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.

Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.

Oncothyreon (ONTY)

Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.

Provectus Pharmaceuticals, Inc. (PVCT)

Provectus Pharmaceuticals, Inc., with its home office in Knoxville, Tennessee, is developing advanced prescription drugs in the fields of oncology and dermatology. Clinical trials of our cancer drug PV-10 for the treatment of melanoma, breast cancer, and liver cancer are currently being conducted. PH-10, our topical formulation of Rose Bengal, is also in clinical trials for psoriasis, atopic dermatitis, and eczema.